SANDOZ CEFTRIAXONE POWDER FOR SOLUTION

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Sẵn có từ:

SANDOZ CANADA INCORPORATED

Mã ATC:

J01DD04

INN (Tên quốc tế):

CEFTRIAXONE

Liều dùng:

2G

Dạng dược phẩm:

POWDER FOR SOLUTION

Thành phần:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 2G

Tuyến hành chính:

INTRAMUSCULAR

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

THIRD GENERATION CEPHALOSPORINS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0117292002; AHFS:

Tình trạng ủy quyền:

CANCELLED PRE MARKET

Ngày ủy quyền:

2018-08-01

Đặc tính sản phẩm

_ _
PRODUCT MONOGRAPH
SANDOZ CEFTRIAXONE
Sterile Ceftriaxone for Injection BP
1 G AND 2 G CEFTRIAXONE PER VIAL (INCORPORATED AS CEFTRIAXONE SODIUM)
ANTIBIOTIC
Sandoz Canada Inc.
Date of Revision: January 15, 2010
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
CONTROL # : 133307
_Sandoz Ceftriaxone _
_ Page 2 of 51_
_ _
TABLE OF CONTENTS
HEALTH PROFESSIONAL
INFORMATION.........................................................................
3
ACTION
.....................................................................................................................................
3
INDICATIONS AND CLINICAL
USES...................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS...............................................................................................................................
4
PRECAUTIONS.........................................................................................................................
6
ADVERSE
REACTIONS...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
....................................................... 10
DOSAGE AND
ADMINISTRATION.....................................................................................
10
ADMINISTRATION................................................................................................................
11
PHARMACEUTICAL
INFORMATION.................................................................................
13
DRUG
SUBSTANCE...............................................................................................................
13
DRUG
PRODUCT....................................................................................................................
13
RECONSTITUTION
.......................................................................................